Press Releases

Date Headline
5/4/2022
Zymeworks Provides Corporate Update and Reports First Quarter 2022 Financial Results
 Summary
Last patient enrolled ahead of expectations in pivotal trial evaluating zanidatamab as monotherapy in 2L biliary tract cancers (BTC) Two zanidatamab data presentations at ASCO in June: 1L breast cancer and 1L gastroesophageal adenocarcinoma ( GEA ) Presented topoisomerase 1 inhibitor (TOPO1i)  Continue Reading
5/2/2022
Zymeworks Announces Participation in Upcoming Investor Conferences
 Summary
VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--May 2, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference: H.C.  Continue Reading
4/28/2022
Zymeworks Confirms Receipt of Unsolicited, Non-Binding Proposal from All Blue Falcons
 Summary
VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--Apr. 28, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today confirmed it has received an unsolicited, non-binding proposal from All Blue Falcons FZE  Continue Reading
4/28/2022
Zymeworks Reports Last Patient Enrolled in Pivotal Study of Zanidatamab in Treatment of HER2-Expressing Late-Line Biliary Tract Cancer
 Summary
VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--Apr. 28, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that it has completed enrollment in its global HERIZON-BTC-01 pivotal clinical  Continue Reading
4/27/2022
Zymeworks Announces Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
 Summary
VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--Apr. 27, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced, in conjunction with its Asia Pacific partner BeiGene, the acceptance of two abstracts for  Continue Reading
4/19/2022
Zymeworks to Host First Quarter 2022 Results Conference Call
 Summary
VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--Apr. 19, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will report its first quarter 2022 financial results after market close on May  Continue Reading
4/1/2022
Zymeworks Announces Participation in Upcoming Investor Conferences
 Summary
VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--Apr. 1, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in upcoming investor conferences: Wells Fargo  Continue Reading
3/3/2022
Zymeworks Announces Participation in Upcoming Investor Conferences
 Summary
VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--Mar. 3, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in upcoming investor conferences during March:  Continue Reading
2/24/2022
Zymeworks Provides Corporate Update and Reports Year-End 2021 Financial Results
 Summary
Enrollment on track for both pivotal trials of zanidatamab in 1L gastroesophageal adenocarcinoma (GEA) and 2L biliary tract cancer (BTC). Announced submission of abstracts for upcoming clinical data for the 2022 American Society for Clinical Oncology (ASCO) Annual Meeting.  Continue Reading
2/8/2022
Zymeworks to Host Fourth Quarter and Full Year 2021 Results Conference Call
 Summary
VANCOUVER, British Columbia & SEATTLE --(BUSINESS WIRE)--Feb. 8, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will report its fourth quarter and full year 2021 financial results after  Continue Reading
Displaying 31 - 40 of 48
Copyright 2022 , Zymeworks Inc.